AU2020242921B2 - Supraparticle formulations - Google Patents

Supraparticle formulations Download PDF

Info

Publication number
AU2020242921B2
AU2020242921B2 AU2020242921A AU2020242921A AU2020242921B2 AU 2020242921 B2 AU2020242921 B2 AU 2020242921B2 AU 2020242921 A AU2020242921 A AU 2020242921A AU 2020242921 A AU2020242921 A AU 2020242921A AU 2020242921 B2 AU2020242921 B2 AU 2020242921B2
Authority
AU
Australia
Prior art keywords
supraparticles
sps
another example
payload
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020242921A
Other languages
English (en)
Other versions
AU2020242921A1 (en
Inventor
Mattias Björnmalm
Frank Caruso
Yutian MA
Andrew Wise
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Bionics Institute
Original Assignee
University of Melbourne
Bionics Institute of Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019900910A external-priority patent/AU2019900910A0/en
Application filed by University of Melbourne, Bionics Institute of Australia filed Critical University of Melbourne
Publication of AU2020242921A1 publication Critical patent/AU2020242921A1/en
Application granted granted Critical
Publication of AU2020242921B2 publication Critical patent/AU2020242921B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5115Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526Head electrodes
    • A61N1/0541Cochlear electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36036Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of the outer, middle or inner ear
    • A61N1/36038Cochlear stimulation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2020242921A 2019-03-19 2020-03-19 Supraparticle formulations Active AU2020242921B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019900910 2019-03-19
AU2019900910A AU2019900910A0 (en) 2019-03-19 Improved supraparticles II
PCT/AU2020/050260 WO2020186304A1 (en) 2019-03-19 2020-03-19 Supraparticle formulations

Publications (2)

Publication Number Publication Date
AU2020242921A1 AU2020242921A1 (en) 2021-10-07
AU2020242921B2 true AU2020242921B2 (en) 2025-04-03

Family

ID=72518918

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020242921A Active AU2020242921B2 (en) 2019-03-19 2020-03-19 Supraparticle formulations

Country Status (6)

Country Link
US (1) US12551450B2 (https=)
EP (1) EP3941442A4 (https=)
JP (1) JP2022525945A (https=)
CN (1) CN114040753A (https=)
AU (1) AU2020242921B2 (https=)
WO (1) WO2020186304A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117065055B (zh) * 2022-05-24 2025-08-29 天津医科大学第二医院 一种核壳型纳米酶探针及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019056062A1 (en) * 2017-09-20 2019-03-28 The Bionics Institute Of Australia SUPERPARTICLES IMPROVED

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468498A (en) 1980-06-12 1984-08-28 Rohm And Haas Company Sequential heteropolymer dispersion and a particulate materal obtainable therefrom, useful in coating compositions as a thickening and/or opacifying agent
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US5157084A (en) 1990-10-12 1992-10-20 The Dow Chemical Company Process of making hollow polymer latex particles
US5521253A (en) 1990-10-12 1996-05-28 The Dow Chemical Company Hollow polymer latex particles
SE9101853D0 (sv) * 1991-06-17 1991-06-17 Jonas Wadstroem Improved tissue ashesive
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
JP4116683B2 (ja) * 1997-02-28 2008-07-09 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 徐放性局所送達製剤
WO2003065881A2 (en) * 2002-02-06 2003-08-14 Orbus Medical Technologies Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
WO2006037160A1 (en) 2004-10-05 2006-04-13 The University Of Melbourne Porous polyelectrolyte materials
CN100558403C (zh) * 2006-10-23 2009-11-11 中国科学院理化技术研究所 双壳层药物缓控释载体材料及其制备方法和用途
BRPI0806803A2 (pt) * 2007-01-19 2011-09-13 Iams Company composição e método de ingrediente sensìvel estabilizado
CN103467755B (zh) * 2013-09-18 2015-06-17 薛巍 一种药物缓释水凝胶及其制备方法与用途
WO2018013928A1 (en) * 2016-07-14 2018-01-18 University Hospitals Cleveland Medical Center Compositions and methods for collagen-based sutures and antibacterial coatings
CN108384031B (zh) * 2017-06-27 2020-10-27 中南民族大学 一种缓释水凝胶载体材料的制备方法和应用
CN107375196B (zh) * 2017-07-26 2020-02-07 暨南大学 一种含儿茶酚基天然多糖复合水凝胶载体及其制备方法
CN107865822A (zh) * 2017-08-25 2018-04-03 中南民族大学 一种掺入纳米介孔二氧化硅的水凝胶药物缓释载体材料的制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019056062A1 (en) * 2017-09-20 2019-03-28 The Bionics Institute Of Australia SUPERPARTICLES IMPROVED

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MA et al.: "Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery", ACS APPLIED MATERIALS & INTERFACES, 2018, vol. 10, no. 37, pages 31019 - 31031, DOI: 10.1021/acsami.8b10415 *
MAINA et al.: "Mold-Templated Inorganic-Organic Hybrid Supraparticles for Codelivery of Drugs", BIOMACROMOLECULES, 2014, vol. 15, no. 11, pages 4146 - 4151, DOI: 10.1021/bm501171j *

Also Published As

Publication number Publication date
EP3941442A4 (en) 2022-12-21
US12551450B2 (en) 2026-02-17
US20220168228A1 (en) 2022-06-02
CN114040753A (zh) 2022-02-11
JP2022525945A (ja) 2022-05-20
WO2020186304A1 (en) 2020-09-24
EP3941442A1 (en) 2022-01-26
AU2020242921A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20250205308A1 (en) Supraparticles
Pramanik et al. Chitosan alchemy: transforming tissue engineering and wound healing
US11213490B2 (en) Encapsulation-free controlled protein release system
US20130196915A1 (en) Affinity hydrogels for controlled protein release
Ma et al. Engineering biocoatings to prolong drug release from supraparticles
CN107660220A (zh) 超支化聚合物和多聚复合物及包含其的dna或rna递送系统
Li et al. An injectable, self-healing and degradable hydrogel scaffold as a functional biocompatible material for tissue engineering applications
CN110124103B (zh) 一种用于组织修复的活性物质缓释材料体系及其制备方法
Ning et al. Recent developments in controlled release of antibiotics
AU2020242921B2 (en) Supraparticle formulations
Lu Polymer-Ceramic Hybrid Nanoparticles: Promising Strategies for Controlled Drug Release
KR101629563B1 (ko) 성장인자를 함유한 생분해용 폴리머-쉘화된 메소포러스 나노구가 삽입된 치료용 폼 스캐폴드
US20240423903A1 (en) Biodegradable Implant for Sustained Trans-Nasal Delivery of Therapeutic Agents to the Brain
Grigoras Pullulan-based hydrogels
Martins et al. Delivery Systems Made of Natural‐Origin Polymers for Tissue Engineering and Regenerative Medicine Applications
Razavi et al. Naturally based and biologically derived nanobiomaterials
Popa et al. Chitosan-Pectin Composite Biomaterials: Types, Interactions, Formulations, and Biomedical Applications
Jose et al. Alginate Hydrogel and Aerogel
Hosseinpour et al. Nanobiomaterials in Craniofacial Bone Regeneration
Kumar et al. Polymer implants for gene and drug delivery
Popa et al. Chitosan-Pectin Composite Biomaterials: Types, Interactions, Formulations, and Biomedical
Nascimento et al. Hybrid Smart Materials for Topical Drug Delivery: Application of Scaffolds
Hudson MNV Ravi Kumar

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)